8 completed, 2 terminated, 1 recruiting, 1 withdrawn. 12 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 8, Terminated 2, Recruiting 1, Withdrawn 1 |
| Phase 1 | 5 | Completed 4, Withdrawn 1 |
Follow Marqibo: new trials by email Literature Review of Marqibo trials Research Report on Marqibo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome - Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2021-01-21 | 2022-01-28 | |
| Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia Bortezomib, Clofarabine, Cyclophosphamide - Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 42 | 2017-08-09 | 2026-08-10 |
| Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma Lenalidomide, Rituximab, Prednisone - Primary Effusion Lymphoma, B-Cell Neoplasm | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2017-07-03 | 2026-11-12 |
| Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Vincristine Sulfate Liposome, Laboratory Biomarker Analysis - Recurrent Adult Acute Myeloid Leukemia | Phase 2 | Terminated | Wake Forest University Health Sciences | 5 | 2015-06-05 | 2019-08-14 |
| Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia Rituximab, Imatinib, Cyclophosphamide - Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 31 | 2013-03-05 | 2022-09-27 |
| Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Cixutumumab, Cyclophosphamide, Dactinomycin - Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 175 | 2010-01-01 | 2017-08-29 |
| Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia cyclophosphamide, cytarabine, dexamethasone - Leukemia | Phase 2 | Terminated | OHSU Knight Cancer Institute | 11 | 2009-06-01 | 2023-01-06 |
| Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 148 | 2009-03-01 | 2017-01-27 |
| Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone - Recurrent Childhood Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 134 | 2005-02-01 | 2017-12-12 |
| Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Vincristine Sulfate Liposomes Injection, Dexamethasone - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Acrotech Biopharma Inc. | 36 | 2002-07-01 | 2019-12-12 |
| Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL Vincristine Sulfate Liposome Injection plus rituximab - Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Completed | Acrotech Biopharma Inc. | 22 | 2001-09-01 | 2020-01-03 |
| Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Etoposide, Rituximab, Prednisone - Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 348 | 1993-05-08 | 2025-06-22 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Burkitt Lymphoma (3) · Leukemia (2) · Lymphoma, Large B-Cell, Diffuse (2) · Leukemia, Myeloid, Acute (1) · Lymphoma, AIDS-Related (1) · Lymphoma, B-Cell (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, Primary Effusion (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Rhabdomyosarcoma (1) · Sarcoma (1)
National Cancer Institute (NCI) (4) · Acrotech Biopharma Inc. (2) · M.D. Anderson Cancer Center (2) · Children's Oncology Group (1) · OHSU Knight Cancer Institute (1) · Roswell Park Cancer Institute (1) · Wake Forest University Health Sciences (1)
United States (12) · Australia (3) · Canada (3) · Puerto Rico (2) · New Zealand (1) · United Kingdom (1)
Brandon Hayes-Lattin (1) · Deborah Thomas, MD (1) · Elias Jabbour, MD (1) · Elizabeth Raetz, MD (1) · Eunice S Wang (1) · Gareth Morgan, Prof. (1) · Lawrence Kaplan, MD (1) · Leonard Heffner, MD (1) · Mark J Roschewski, M.D. (1) · Maro Ohanian (1) · Ramya Ramaswami, MBBS, MPH (1) · Suman Malempati, MD (1) · Terzah Horton, MD PhD (1) · Timothy Pardee (1) · Wendy Stock, MD (1)
PMID 23574119, PMID 24224624, PMID 25024303, PMID 28419486, PMID 29748435, PMID 30125215, PMID 30957229, PMID 34432874, PMID 35882475
U10CA098543 (3), U10CA180886 (2), P30CA012197 (1)